IMWG Consensus statement on the role of 18F-FDG PET/CT in the diagnosis and management of myeloma and related diseases

This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the optimal use of  18F-FDG PET/CT in the diagnosis and management of multiple myeloma and related diseases, including smouldering myeloma and solitary plasmacytoma.

Read article

Diagnostic tests and prognostic indicators

Diagnostic accuracy of computed tomography-guided biopsy in pathological fractures. Stokes CM et al. ANZ J Surg. 2017 Mar 17. doi: 10.1111/ans.13894. [Epub ahead of print]. Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma. Dutoit JC et al. Skeletal Radiol. 2017 Mar 13. doi: 10.1007/s00256-017-2609-6. [Epub ahead of print]. CXCR4 (CD184) expression on stem cell harvest and…

Details

Related conditions

POEMS Syndrome: an Enigma. Warsame R et al. Curr Hematol Malig Rep. 2017 Mar 15. doi: 10.1007/s11899-017-0367-0. [Epub ahead of print]. Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept. Ramirez-Alvarado M et al. Am J Hematol. 2017 Mar 10. doi: 10.1002/ajh.24717. [Epub ahead of print]. The risk of renal disease is increased in…

Details

Emerging treatments

Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Shah N et al. Br J Haematol. 2017 Mar 14. doi: 10.1111/bjh.14570. [Epub ahead of print]. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Sborov DW et al. Leuk Lymphoma. 2017 Mar 7:1-9. doi: 10.1080/10428194.2017.1298751.…

Details

Biology and genetics

p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. Tessoulin B et al. Blood Rev. 2017 Mar 4. pii: S0268-960X(16)30059-5. doi: 10.1016/j.blre.2017.03.001. [Epub ahead of print]. Mesenchymal stromal cells enhance the suppressive effects ofmyeloid-derived suppressor cells of multiple myeloma. Xu Y et al. Leuk Lymphoma. 2017 Mar 20:1-9. doi: 10.1080/10428194.2017.1298753. [Epub ahead of print]. Identification of…

Details

General

Update on the optimal use of bortezomib in the treatment of multiple myeloma. Mohan M et al. Cancer Manag Res. 2017 Mar 2;9:51-63. doi: 10.2147/CMAR.S105163. eCollection 2017. Multiple Myeloma: Diagnosis and Treatment. Michels TC et al. Am Fam Physician. 2017 Mar 15;95(6):373-383. Monoclonal antibody therapy in multiple myeloma. Touzeau C et al. Leukemia. 2017 Mar 10. doi: 10.1038/leu.2017.60. [Epub ahead of print]. Patients with myeloma need more time…

Details

Supportive treatments

Reinforced cementoplasty using dedicated spindles in the management of unstable malignant lesions of the cervicotrochanteric region. Premat K et al. Eur Radiol. 2017 Mar 13. doi: 10.1007/s00330-017-4774-3. [Epub ahead of print]. Biosimilar Retacrit® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) – non-interventional study. Losem C et al. Onco Targets Ther. 2017 Feb…

Details

Complications of myeloma and its treatments

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. Sidana S et al. PLoS One. 2017 Mar 9;12(3):e0172996. doi: 10.1371/journal.pone.0172996. eCollection 2017. Late recurrence of autologous GvHD in a myeloma patient: a myth or diagnostic challenge? El-Jurdi N et al. Bone Marrow Transplant. 2017 Mar 20. doi: 10.1038/bmt.2017.20. [Epub ahead of print]. Long-term control of extensive refractory chronic…

Details

Current treatments

Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (“VCD-Lite”) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. Tuchman SA et al. J Geriatr Oncol. 2017 Feb 27. pii: S1879-4068(17)30030-9. doi: 10.1016/j.jgo.2017.02.004. [Epub ahead of print]. Carfilzomib containing combinations as frontline therapy for multiple myeloma: a meta analysis of 13 trials. Sheng Z et al. Eur J Haematol. 2017…

Details

Diagnostic techniques and prognostic indicators

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Chavan SS et al. Blood Cancer J. 2017 Feb 24;7(2):e535. doi: 10.1038/bcj.2017.12. CD117 (KIT) Is A Useful Marker in The Diagnosis of Plasmablastic Plasma Cell Myeloma. Marks E et al. Histopathology. 2017 Feb 22. doi: 10.1111/his.13196. [Epub ahead of print]. In vivo confocal microscopy of multiple myeloma associated…

Details